Jun
8
2022
On demand
Life on a chip - vascularized micro-tumor chips for mimicking clinical drug responses
Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
In this webinar, you will learn about cutting-edge organ chip technology already in use by several of the top pharmaceutical companies for drug development and immuno-oncology applications. Most cells in our body are no farther from a blood vessel than the width of a hair. Blood vessels help pattern tissues and provide them with their nutrients, and since almost all therapeutics — whether small molecules, antibodies, or leukocytes — reach our tissues via blood vessels, no model of tissue-drug interaction is realistic without this supporting vascular network. You will learn what readouts are available in vitro for developing drug, cell and gene-based therapies, including:
- Continual imaging of tumor growth and response to drugs
- Imaging of leukocyte vascular adhesion & extravasation
- Assessment of tumor occupancy and killing by leukocytes, including CAR-Ts
- Assessment of monoclonal antibody & bispecific delivery and efficacy
- Assessment of target gene expression by in situ staining or qPCR
- Collection of venous outflow for assessment of biomarkers
Attend this webinar to learn:
- How responses in Vascularized Micro-Tumor chips compare to responses seen in patient tumors
- What types of drug, cell-based and gene therapy studies can be conducted using Vascularized-Micro Tumor chips
- How Vascularized Micro-Tumor chips compare to other models, such as 2D cell culture or spheroid models
SPEAKERS
You might also like
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
Ryan Massopust
11 June
Watch
Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency
K Doucette, F Vass, K Bertram
25 July
Watch
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
Meredith Safford, ShaNelle Yelity
22 May
Watch
Advancing LNP characterization for drug delivery: NeoVac
T Kovačič, B Bakalar, D Peer
8 October
Watch
Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness
K Watanabe, M Sadik, M Duggan
7 March
Watch